European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
All content for European Pharmaceutical Review podcast is the property of European Pharmaceutical Review and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
In this podcast, Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals discusses the clinical development and manufacturing of RNA interference (RNAi) therapeutics.
RNA interference (RNAi) medicines that can ‘silence’ or turn off the production of specific genes that cause or contribute to disease, are one of the exciting emerging modalities in drug development today.
In this episode, EPR Editor Caroline Peachey catches up with Dr Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals to explore clinical development and manufacturing of RNAi medicines for large patient populations.
European Pharmaceutical Review podcast
European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
